361 Capital’s Gilead Sciences GILD Stock Holding History

361 Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,213	Closed	-$457K	–	349
2019 Q3	$457K	Sell	7,213 -60	-0.8%	-$3.92K	0.08%	288
2019 Q2	$491K	Buy	+7,273	New	+$478K	0.09%	274
2019 Q1	–	Sell	-18,331	Closed	-$1.15M	–	354
2018 Q4	$1.15M	Buy	+18,331	New	+$1.28M	0.23%	195
2017 Q4	–	Sell	-49,772	Closed	-$4.03M	–	265
2017 Q3	$4.03M	Buy	+49,772	New	+$3.81M	0.77%	24

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

361 Capital's GILD Position: Q4 2019 in Review

361 Capital sold out of Gilead Sciences (GILD) in Q4 2019, closing a stake of 7,213 shares — an estimated $457K sold.

361 Capital first reported a position in GILD in Q3 2017 and held it in 4 quarters. The position peaked at $4.03M in Q3 2017. 1,555 funds tracked by Wall St. Rank hold GILD as of Q4 2019.

361 Capital reported no remaining Gilead Sciences position as of Q4 2019 after selling out during the quarter.
361 Capital sold 7,213 Gilead Sciences shares in Q4 2019, an estimated $457K.
361 Capital first reported a position in Gilead Sciences in Q3 2017 and held it in 4 quarters.
361 Capital's Gilead Sciences position peaked at $4.03M in Q3 2017.
1,555 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2019.

Based on 361 Capital's 13F filing for Q4 2019, filed 13 Feb 2020.